Seung Suh Hong
Direttore/Membro del Consiglio presso OCULAR THERAPEUTIX, INC.
Patrimonio netto: 87 919 $ in data 30/04/2024
Profilo
Seung Suh Hong's current job(s) include Vice Chairman at Novalgen Ltd., Vice Chairman at Novelgen Co. Ltd(South Korea), Independent Director at Ocular Therapeutix, Inc., and President & Chief Operating Officer at Cellemedy Co., Ltd.
.
Dr. Hong's former job(s) include President & Chief Executive Officer at Celltrion Healthcare Co., Ltd.
from 2002 to 2015, and President at Celltrion Healthcare Japan KK from 2016 to 2019.
Dr. Hong's education history includes undergraduate, graduate, and doctorate degrees from Seoul National University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
OCULAR THERAPEUTIX INC
0.01% | 14/06/2023 | 20 933 ( 0.01% ) | 87 919 $ | 30/04/2024 |
Posizioni attive di Seung Suh Hong
| Società | Posizione | Inizio |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Direttore/Membro del Consiglio | 11/06/2019 |
Cellemedy Co., Ltd.
 Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Presidente | 01/01/2021 |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/01/2021 |
| Novelgen Co. Ltd(South Korea) | Direttore/Membro del Consiglio | 01/04/2020 |
Precedenti posizioni note di Seung Suh Hong
| Società | Posizione | Fine |
|---|---|---|
| Celltrion Healthcare Japan KK | Presidente | 02/01/2019 |
| CELLTRION HEALTHCARE CO., LTD. | Amministratore Delegato | 01/12/2015 |
Formazione di Seung Suh Hong
| Seoul National University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| CELLTRION HEALTHCARE CO., LTD. | Health Technology |
| Aziende private | 4 |
|---|---|
| Celltrion Healthcare Japan KK | |
Cellemedy Co., Ltd.
Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Commercial Services |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
| Novelgen Co. Ltd(South Korea) |
- Borsa valori
- Insiders
- Seung Suh Hong
